| 朱筱婧,喻正科,姜泱,等.天丹降压方联合西药治疗冠心病合并心力衰竭的临床疗效观察[J].江苏中医药,,():. |
| 天丹降压方联合西药治疗冠心病合并心力衰竭的临床疗效观察 |
| Clinical Observation of Tiandan Jiangya Prescription combined with Western Medicine in the Treatment of Coronary Heart Disease Complicated with Heart FailureZhu Xiaojing, Yu Zhengke, Jiang Yang, Yan Xu * |
| 投稿时间：2024-01-04 修订日期：2024-02-26 |
| DOI： |
| 中文关键词: 天丹降压方 冠心病 心力衰竭 临床疗效 心功能 |
| 英文关键词: Tiandan Jiangyoufang Coronary heart disease Heart failure Clinical effect Cardiac function |
| 基金项目:2023年度省自科基金青年基金(课题编号 2023JJ40399) |
|
| 摘要点击次数: 2 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的:探讨天丹降压方对冠心病合并心力衰竭患者的临床疗效。方法:选取2021年1月-2023年2月于我院收治的冠心病合并心力衰竭患者128例,根据治疗方案将其分为对照组和联合组,对照组(酒石酸美托洛尔片+螺内酯片,n=64)、联合组(酒石酸美托洛尔片+螺内酯片+天丹降压方,n=64)。分析治疗前后两组治疗效果、中医证候积分、心功能、血液指标,以及不良反应和生活质量。结果:治疗结束,联合组治疗疗效96.88%(62/64)高于西医组82.81%(53/64)(x2=6.935,P=0.010)。两组中医症候积分均较治疗前降低(P<0.05),联合组低于西医组(P<0.05)。两组左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、均降低,左心室射血分数(LVEF)、心脏指标每搏输出量(SV)、心排血指数(CI)均上升,联合组LVEDD、LVESD下降水平和LVEF、SV、CI上升水平均比对照组更高(P<0.05)。两组血浆氨基末端脑钠肽(NT-proBNP)、血小板活化因子(PAF)均降低,且联合组下降水平更高(P<0.05)。联合组的不良反应发生率(6.25%)低于对照组(18.75%),(P<0.05)。两组生活质量评分均上升(P <0.05),且联合组更高(P<0.05)。结论:天丹降压方联合西药治疗冠心病合并心力衰竭,能有效提高临床疗效和降低中医证候积分,可抑制患者的血小板活化,有效改善患者心功能,降低不良反应发生率,提高患者生活质量。 |
| 英文摘要: |
| Objective: To investigate the clinical effect of Tiandan Jiangya prescription on patients with coronary heart disease complicated with heart failure. Methods: A total of 128 patients with CHD combined with heart failure admitted to our hospital from January 2021 to February 2023 were selected and divided into control group and combination group according to the treatment plan, control group (metoprolol tartrate tablet + spironolactone tablet, n=64) and combination group (metoprolol tartrate tablet + spironolactone tablet + Tiandan antihypertension prescription, n=64). The therapeutic effect, TCM syndrome score, heart function, blood index, adverse reactions and quality of life of the two groups before and after treatment were analyzed. Results: At the end of treatment, the curative effect of combination group was 96.88% (62/64) higher than that of western group (82.81% (53/64) (x2=6.935, P=0.010). The scores of TCM symptoms in both groups were lower than those before treatment (P<0.05), and those in combination group were lower than those in western medicine group (P<0.05). Left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) decreased in both groups, while left ventricular ejection fraction (LVEF), cardiac index stroke output (SV) and cardiac output index (CI) increased. The decrease level of LVEDD and LVESD and the increase level of LVEF, SV and CI in combination group were higher than those in control group (P<0.05). Plasma amino terminal brain natriuretic peptide (NT-proBNP) and platelet activating factor (PAF) were decreased in both groups, and the decreased level was higher in the combined group (P<0.05). The incidence of adverse reactions in combination group (6.25%) was lower than that in control group (18.75%) (P<0.05). Quality of life scores increased in both groups (P<0.05), and higher in the combined group (P<0.05). Conclusion: Tiandan Jiangya formula combined with Western medicine in the treatment of coronary heart disease complicated with heart failure can effectively improve clinical efficacy and reduce TCM syndrome score, inhibit platelet activation, effectively improve patients" heart function, reduce the incidence of adverse reactions, and improve patients" quality of life. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
